<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BEACOPP (<z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, procarbazine and <z:chebi fb="0" ids="8382">prednisone</z:chebi>) escalated is the preferred upfront Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) treatment in a number of countries </plain></SENT>
<SENT sid="1" pm="."><plain>Upon failure, high-dose chemotherapy with autologous stem cell support (HDT/ASCT) is performed, but its effectiveness has not been verified in this setting </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed <z:hpo ids='HP_0000001'>all</z:hpo> Swiss cases of chemosensitive <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> autografted after failure of BEACOPP escalated (n = 22) and compared outcomes with 22 cases of HDT/ASCT following frontline ABVD (<z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, vinblastine and <z:chebi fb="0" ids="4305">dacarbazine</z:chebi>) failure </plain></SENT>
<SENT sid="3" pm="."><plain>Five-year progression-free survival (PFS) was 76% for ABVD and 42% for BEACOPP escalated (p = 0.029) </plain></SENT>
<SENT sid="4" pm="."><plain>Two- and 5-year overall survival (OS) was 90% and 71% for ABVD and 72% and 65% for BEACOPP escalated, respectively (p = not significant) </plain></SENT>
<SENT sid="5" pm="."><plain>Three patients in the ABVD and four in the BEACOPP escalated groups underwent allotransplant for relapse after HDT/ASCT </plain></SENT>
<SENT sid="6" pm="."><plain>Grade 3-4 toxicities were comparable in both groups </plain></SENT>
<SENT sid="7" pm="."><plain>Three cases of therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were recorded in the BEACOPP escalated group </plain></SENT>
<SENT sid="8" pm="."><plain>The acceptable PFS and OS of chemosensitive patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> autografted after failure of upfront BEACOPP escalated seem to justify this approach </plain></SENT>
</text></document>